title: Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014.
authors.affiliation: BioNTech RNA Pharmaceuticals GmbH, An der Goldgrube 12, 55131, Mainz, Germany, bjoern.kloke@biontechrna.de.
authors.forename: Björn-Philipp
authors.initials: BP
authors.lastname: Kloke
authors.forename: Andrea
authors.initials: A
authors.lastname: Mahr
authors.forename: Robert A
authors.initials: RA
authors.lastname: Jabulowsky
authors.forename: Sarah
authors.initials: S
authors.lastname: Kutscher
authors.forename: Richard
authors.initials: R
authors.lastname: Rae
authors.forename: Cedrik M
authors.initials: CM
authors.lastname: Britten
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D060908:CTLA-4 Antigen / Q000276:immunology; D019496:Cancer Vaccines / Q000627:therapeutic use; D005858:Germany; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D059016:Tumor Microenvironment / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines; D000074324:Ipilimumab